FENC 株価分析 — FENNEC PHARMACEUTICALS INC (Healthcare >> Biotechnology)
FENC に関するよくある質問
FENCのPER(株価収益率)は?
FENNEC PHARMACEUTICALS INC(FENC)は現在PER 1,712.66倍で取引されています。
FENCのROE(自己資本利益率)は?
FENNEC PHARMACEUTICALS INCのROEは-22.23%です。
FENCの配当利回りは?
FENNEC PHARMACEUTICALS INCの配当利回りは0.00%です。
FENCの品質スコア(Quality Score)は?
当社のAIはFENCの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
FENCは今が買い時ですか?
当社AIのタイミングスコアは100点中70点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
FENCはどのセクターに属しますか?
FENNEC PHARMACEUTICALS INCはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
FENC AI Analysis Summary
Our AI summary for FENC: FENNEC PHARMACEUTICALS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 1,712.66, ROE of -22.23%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 70/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 9.57
Price
-0.34
(-3.43%)
Day Change
|
|
|---|
FENC, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 79 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 9.57 |
| PBV / Sector |
9.14 / 5.20
|
| Earning Per Share | -0.23 |
| PE / Sector |
1,712.66 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
2.70 / 1.22
|
| Average 1M Daily Value |
1.47 M
GREAT
|
| Average 1W Daily Value |
0.94 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:50 |
| Symbol | FENC |
| Name | FENNEC PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 34.74 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 344.24 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709
Phone: 919 636 4530
Website: https://www.fennecpharma.com
Sector: Healthcare >> Biotechnology
Description: Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google